Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
Takeda Pharmaceutical’s Chief Medical Officer, Farajallah Awny Samaan Botros, reported his initial shareholdings in the company. He holds 112,629 American Depositary Shares directly, including 73,220 restricted stock units that convert into ADSs as they vest on scheduled dates from July 1, 2026 through July 1, 2028.
Takeda Pharmaceutical executive Ibrahim Ramy Riad Ahmed filed an initial statement of ownership, reporting 84,787 American Depositary Shares of the company. This total includes 48,928 restricted stock units (RSUs), each convertible into one ADS. The RSUs vest in stages on July 1, 2026 (24,022 shares), July 1, 2027 (16,554 shares) and July 1, 2028 (8,352 shares), showing a multi‑year equity-based compensation structure tied to his role as President of the PDT business unit.
Takeda reported strong Phase 3 results for its investigational oral TYK2 inhibitor zasocitinib (TAK-279) in adults with moderate‑to‑severe plaque psoriasis. In two large global LATITUDE PsO studies, about 70% of patients on zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16, far exceeding placebo and apremilast.
Zasocitinib also drove high rates of deeper responses: over half of treated patients reached PASI 90 at week 16, and roughly one‑third achieved complete skin clearance (PASI 100 and sPGA 0), with responses improving through week 24. More than 90% of responders who stayed on drug at week 40 maintained sPGA 0/1, PASI 75 and PASI 90 through week 60, indicating durable control.
The once‑daily pill showed a safety profile consistent with earlier trials, with treatment‑emergent adverse events in 62.1% of zasocitinib patients versus 46.9% on placebo and 50.5% on apremilast; the most common were upper respiratory infection, nasopharyngitis and acne, and no new safety signals were seen. Takeda plans to begin New Drug Application filings in fiscal 2026, targets a first psoriasis launch in the first half of 2027, and cites combined psoriasis and psoriatic arthritis peak revenue potential of $3‑6B, though these results do not change its full‑year forecast to March 31, 2026.
Takeda Pharmaceutical Company Limited is advancing its leadership transition and Board renewal. The Board will propose CEO-elect Julie Kim as a new internal director at the 150th Ordinary General Meeting of Shareholders on June 24, 2026. If elected, she will be appointed representative director, president & CEO immediately after the meeting, while current representative director, president & CEO Christophe Weber plans to retire from Takeda and its Board on the same day.
Takeda is also reshaping its Board with three new external candidates – Bruce Broussard, Koichiro Kimura and Paul Stoffels – and the planned retirement of six current external directors. All other current Board members are expected to be proposed for re-election. An attachment notes that Julie Kim holds 173,773 ADSs and outlines her prior leadership roles at Shire and Takeda, reinforcing her experience ahead of assuming the top role.
Takeda Pharmaceutical Company Limited is launching the next phase of its global transformation program to boost competitiveness and support multiple upcoming drug launches. The company targets annualized gross savings of more than JPY 200 billion by FY2028, mainly through streamlined corporate functions, simpler processes and better use of technology.
These efficiencies are expected to largely offset investments in launch preparations for medicines such as oveporexton, rusfertide and zasocitinib, as well as late-stage pipeline and technology spending. Takeda currently estimates restructuring expenses of about JPY 150 billion in FY2026, with smaller charges in FY2027 and FY2028. The initiatives are not expected to have a significant impact on the full-year consolidated financial forecast for FY2025.
Takeda Pharmaceutical CEO-elect Julie So-Young Kim has filed an initial ownership report showing beneficial ownership of 324,729 American Depositary Shares. This total includes 150,956 restricted stock units (RSUs), each convertible into one ADS. The RSUs vest in stages: 70,110 on July 1, 2026, 52,218 on July 1, 2027, and 28,628 on July 1, 2028, highlighting a multi-year, equity-based incentive structure aligned with her leadership role.
TAKEDA PHARMACEUTICAL CO LTD Global General Counsel Natalie Anne Marie Furney filed an initial ownership report showing an award of 191,280 restricted stock units (RSUs), each representing a contingent right to receive one American Depositary Share.
The RSUs vest in three equal-time tranches: 63,758 on July 1, 2026, 63,758 on July 1, 2027 and 63,764 on July 1, 2028.
Takeda Pharmaceutical executive Teresa Marie Bitetti, President of the Oncology Business Unit, reports beneficial ownership of 193,148 American Depositary Shares. This total includes 85,802 restricted stock units, each convertible into one ADS.
The RSUs are scheduled to vest in three tranches: 40,056 shares on July 1, 2026, 30,564 shares on July 1, 2027, and 15,182 shares on July 1, 2028, providing a clearly defined equity vesting timeline.
Takeda Pharmaceutical filed an initial ownership report for Global Business Development Officer Marcello Pignagnoli Agosti. He reports direct ownership of 144,608 American Depositary Shares. This total includes 53,850 restricted stock units, each representing one ADS, vesting on July 1, 2026, July 1, 2027, and July 1, 2028 in scheduled installments.
Takeda Pharmaceutical director Yoshiaki Fujimori filed an initial ownership report listing his equity interests in the company. He directly holds 27,865 Ordinary Shares. The filing also notes 8,400 restricted stock units (RSUs), each representing a right to receive one Ordinary Share as they vest.
The RSUs vest on June 1, 2026 (2,100 shares), June 1, 2027 (2,200 shares), June 1, 2028 (2,100 shares) and upon retirement from board service (2,000 shares). Separate Tax Obligation Awards are described as economically equivalent to Ordinary Shares but payable in cash primarily to cover tax obligations at future vesting.